Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer

A. V. D'Amico, R. Whittington, S. B. Malkowicz, D. Schultz, B. Silver, Henry T. Lynch, M. Hurwitz, I. Kaplan, C. J. Beard, J. E. Tomaszewski, A. A. Renshaw, A. Wein, J. P. Richie

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The clinical utility of the percent of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome following radical prostatectomy (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated. After accounting for the established prognostic significance of the PSA level, biopsy Gleason score and the clinical T-stage, the percent of positive prostate biopsies added clinically significant information regarding time to PSA failure following RP. These findings were validated in the intermediate risk patients using an independent surgical and radiation data set.

Original languageEnglish (US)
Pages (from-to)259-264
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume3
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostate
Prostatic Neoplasms
Biopsy
Prostatectomy
Neoplasm Grading
Therapeutics
Radiotherapy
Radiation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology
  • Cancer Research

Cite this

Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. / D'Amico, A. V.; Whittington, R.; Malkowicz, S. B.; Schultz, D.; Silver, B.; Lynch, Henry T.; Hurwitz, M.; Kaplan, I.; Beard, C. J.; Tomaszewski, J. E.; Renshaw, A. A.; Wein, A.; Richie, J. P.

In: Prostate Cancer and Prostatic Diseases, Vol. 3, No. 4, 2000, p. 259-264.

Research output: Contribution to journalArticle

D'Amico, AV, Whittington, R, Malkowicz, SB, Schultz, D, Silver, B, Lynch, HT, Hurwitz, M, Kaplan, I, Beard, CJ, Tomaszewski, JE, Renshaw, AA, Wein, A & Richie, JP 2000, 'Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer', Prostate Cancer and Prostatic Diseases, vol. 3, no. 4, pp. 259-264.
D'Amico, A. V. ; Whittington, R. ; Malkowicz, S. B. ; Schultz, D. ; Silver, B. ; Lynch, Henry T. ; Hurwitz, M. ; Kaplan, I. ; Beard, C. J. ; Tomaszewski, J. E. ; Renshaw, A. A. ; Wein, A. ; Richie, J. P. / Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. In: Prostate Cancer and Prostatic Diseases. 2000 ; Vol. 3, No. 4. pp. 259-264.
@article{e20b7f93746f43a6b3985bf74360ef32,
title = "Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer",
abstract = "The clinical utility of the percent of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome following radical prostatectomy (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated. After accounting for the established prognostic significance of the PSA level, biopsy Gleason score and the clinical T-stage, the percent of positive prostate biopsies added clinically significant information regarding time to PSA failure following RP. These findings were validated in the intermediate risk patients using an independent surgical and radiation data set.",
author = "D'Amico, {A. V.} and R. Whittington and Malkowicz, {S. B.} and D. Schultz and B. Silver and Lynch, {Henry T.} and M. Hurwitz and I. Kaplan and Beard, {C. J.} and Tomaszewski, {J. E.} and Renshaw, {A. A.} and A. Wein and Richie, {J. P.}",
year = "2000",
language = "English (US)",
volume = "3",
pages = "259--264",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer

AU - D'Amico, A. V.

AU - Whittington, R.

AU - Malkowicz, S. B.

AU - Schultz, D.

AU - Silver, B.

AU - Lynch, Henry T.

AU - Hurwitz, M.

AU - Kaplan, I.

AU - Beard, C. J.

AU - Tomaszewski, J. E.

AU - Renshaw, A. A.

AU - Wein, A.

AU - Richie, J. P.

PY - 2000

Y1 - 2000

N2 - The clinical utility of the percent of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome following radical prostatectomy (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated. After accounting for the established prognostic significance of the PSA level, biopsy Gleason score and the clinical T-stage, the percent of positive prostate biopsies added clinically significant information regarding time to PSA failure following RP. These findings were validated in the intermediate risk patients using an independent surgical and radiation data set.

AB - The clinical utility of the percent of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome following radical prostatectomy (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated. After accounting for the established prognostic significance of the PSA level, biopsy Gleason score and the clinical T-stage, the percent of positive prostate biopsies added clinically significant information regarding time to PSA failure following RP. These findings were validated in the intermediate risk patients using an independent surgical and radiation data set.

UR - http://www.scopus.com/inward/record.url?scp=0034500480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034500480&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034500480

VL - 3

SP - 259

EP - 264

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -